Treatment of transplanted patients with cyclosporin A (CSA) may cause adverse effects such as nephrotoxicity and hypertension. As CSA is known to induce oxidative stress in several tissues, it may cause vascular problems by triggering oxidative stress in endothelial cells (EC). However, oxidative stress has been reported for acute exposure to CSA concentrations exceeding its clinical range, whereas immunosuppression requires life-long treatment with therapeutic concentrations. We therefore compared the effects of 21 h pharmacological (200 M) vs. 8 days clinical (0.5-2.5 M) doses of CSA on cultured human EC. Pharmacological doses of CSA cause a decrease in cell density via apoptosis and a down-regulation of the antiapoptotic protein Bcl-2. However, these effects are independent of CSA-induced oxidative stress. In contrast, therapeutic concentrations of CSA cause Bcl-2 up-regulation and modification of EC morphology, both effects blocked by antioxidants. Therefore, a low level of oxidants may act in EC as second messengers that up-regulate Bcl-2, thus promoting survival of impaired EC. Our data suggest that the oxidative stress induced by clinical concentrations of CSA may be involved in the adverse effects of the drug on the vascular system of transplanted patients via an adaptive response involving Bcl-2 up-regulation rather than an apoptotic process.-Longoni, B., Boschi, E., Demontis, G. C., Ratto, G. M., Mosca, F. Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels. FASEB J. 15, 731-740 (2001) 
rat hepatocytes (5) and that antioxidants such as vitamin E, melatonin, and other indolic compounds inhibit lipid peroxidation in animal models of cyclosporin A-induced nephrotoxicity (6 -9) suggests a role for oxidative stress in CSA-induced damage. As the endothelium is known to influence vascular tone (10, 11) and is considered to be the main site of impaired vascular regulation by CSA (12) (13) (14) (15) , endothelial cell (EC) damage by oxidative stress may play a key role in the vascular problems of transplanted patients treated with CSA. Accordingly, we have recently shown that CSA induces a concentration-dependent increase in oxidants and lipid peroxidation in cultured human endothelial cells (16) . Considering the well-known relationship between oxidative stress and apoptosis (17, 18) , CSA-induced oxidative stress may damage EC via apoptotic cell death.
However, oxidative stress-induced apoptosis occurs for acute exposure to CSA concentrations outside its therapeutic range (19, 20) , and it is presently unclear whether it may play a causal role in the vascular problems of patients chronically treated with therapeutic doses of CSA.
The main aim of the present work was to provide a better understanding of the pathogenesis of CSA-induced vascular toxicity by comparing its acute (high levels for short time) vs. chronic (low levels for long time) effects on oxidative stress and apoptosis in human EC.
Our study suggests that acute treatment with CSA is associated with apoptosis and with a decrease of Bcl-2 protein expression in EC. On the other hand, chronic treatment with therapeutic levels of CSA affects EC via mechanisms that involve adaptation to CSA-induced oxidative stress through Bcl-2 up-regulation, which may have a key role in promoting the survival of EC with an impaired function, as suggested by their altered morphology.
MATERIALS AND METHODS

Human umbilical vein endothelial cell (HUVEC) cultures
HUVECs were isolated from human umbilical veins as described (21) with minor modifications. After collection, umbilical cords were placed in cold saline solution containing penicillin 25 U/ml and streptomycin 50 g/ml. The umbilical veins were cannulated and perfused with saline solution to wash out the residual blood. Both ends of the cord were clamped and then infused with saline containing 0.25% type IA collagenase. After 10 min incubation at 37°C, the collagenase solution containing detached HUVECs was flushed out of the cord with 10 ml of Medium 199. The cells were then centrifuged at 100 g and resuspended in complete Medium 199 containing 20 mM HEPES buffer, 20% heat-inactivated fetal calf serum, 0.2% growth factor for endothelial cells, 2 mM glutamine, 5 U/ml heparin, 25 U/ml penicillin, and 50 g/ml streptomycin. HUVECs were cultured overnight in 25 cm 2 gelatin-coated tissue culture flasks (Corning, Corning, N.Y.) at 37°C in a NAPCO incubator (5% CO 2 , 95% air). The next day contaminating cells were rinsed out of the flask and 9 ml of complete medium was added. At confluence, HUVECs were trypsinized and plated into three flasks for an additional passage. HUVECs were used for experiments in the third subpassage. HUVECs were identified by their typical cobblestone appearance and positive indirect immunofluorescence for factor VIII. All reagents used for cell dissociation and culture were obtained from Sigma (Milan, Italy).
Phase-contrast microscopy
For phase-contrast microscopy, cells were cultured on 75 cm 2 culture flasks (Greiner) and exposed to experimental conditions. Phase-contrast microscopic examination was performed using an inverted Zeiss Televal 3 (light source 25 W halogen lamp) equipped with a Nikon camera.
Cell density was evaluated by the trypan blue exclusion procedure. The cell suspension was diluted 1:2 with the dye (trypan blue 0.4%, Sigma) prior to counting of viable cells with a hemocytometer.
Monitoring of reactive oxygen species production
For microscopic observation, HUVECs were plated on gelatincoated glass coverslips until they reached subconfluence. The glass coverslip was adapted to a Plexiglas chamber and HUVECs were loaded with 10 M dihydrorhodamine 123 (DHR123) (Molecular Probes, Eugene, Oreg.) for 30 min at 37°C in culture medium. The chamber was positioned for imaging on the stage of an inverted microscope (Nikon Eclipse TE300) equipped with a laser confocal scanning system (Radiance Plus, Bio-Rad, Hercules, Calif.). The stock solution (10 mM) of dihydrorhodamine 123 in DMSO contained less than 1% of contaminating rhodamine 123 (RHD123), as assessed by spectrofluorometry using a PerkinElmer LB50 Fluorescence Spectrometer. Contamination of rhodamine 123 present in traces in the dihydrorhodamine stock was responsible for the low background fluorescence observed at the beginning of the recording session, which did not change in untreated cells over a period of 2 h. Cyclosporin A was added after 15 min of observation (baseline); 2 M SNARF (Molecular Probes) was also included in some experiments to assess cell morphology and viability. Acridine orange (Molecular Probes) was used at 10 g/ml as a membrane permeant and an intercalating agent to label nucleic acids.
Fluorescence images were collected every 3 min using the 488 nm excitation wavelength from an argon laser and the 515 nm emission filter. To minimize photo-oxidation of the probe, the laser beam was attenuated to 50% of maximal illumination and exposure of cells to light was limited to the image acquisition intervals (ϳ2 s every 3 min) via the acquisition software. Analysis of the fluorescent signal was performed with Adobe Photoshop 5.0 (Adobe, San Jose, Calif.) for each cell and for each period of time over a similar region of interest, which included most of the cells. To compensate for the pronounced variability of fluorescence from cell to cell (see Results, Fig. 1A , and Fig. 6A ) that was already present in controls, for each cell the effect of CSA on fluorescence was expressed as the relative increase over the basal value at the beginning of recording. In control experiments, without dihydrorhodamine 123, CSA did not affect the low autofluorescence of HUVECs.
Lactic dehydrogenase (LDH) assay
LDH release was measured as the enzymatic activity present in the cell medium. Media were collected from cell cultures at appropriate times and centrifuged to remove contaminating cells and debris. LDH activity was assessed by standard enzymatic methods (22) .
Lipid peroxidation assay
Lipid peroxidation was evaluated by using a commercial colorimetric kit by Calbiochem (San Diego, Calif.) for malonaldehyde and 4-hydroxyalkenals (MDAϩ4-HNA). MDA ϩ 4-HNA production was determined at different time points in control and CSA-treated cell cultures in accordance with the manufacturer's instructions.
DNA extraction and gel electrophoresis
Endothelial cells (10 7 cells/sample) were washed with NaCl 0.9%, trypsinized, and harvested by centrifugation (100 g for 10 min). The pellet was washed with NaCl 0.9% and resuspended in 500 l of digestion buffer (100 mM NaCl, 10 mM Tris-HCl pH 8, 25 mM Na 2 EDTA pH 8, 0.5% SDS, 0.1 mg/ml proteinase K, and 1% 2-mercaptoethanol). After overnight incubation at 50°C, the samples were extracted twice with phenol/chloroform/isoamyl alcohol (25/24/1) and centrifuged at 10,000 g for 10 min. DNA in the aqueous phase was precipitated by adding to the sample 0.5 volume of 7.5 M ammonium acetate and 2 volumes of ethanol, and recovered by centrifuging at 10,000 g for 2 min. The pellet was rinsed with 70% ethanol and air dried, and DNA was resuspended in TE buffer (10 mM Tris-HCl pH 8, 1 mM Na 2 EDTA pH 8).
Residual RNAs were removed with 1 g/ml DNase-free RNase-A by incubating for 1 h at 37°C. DNA was resolved in 1% agarose gel in the presence of 2 g/ml ethidium bromide and visualized with UV transillumination. Photographs were directly taken with a Polaroid M4 camera.
Bcl-2 and nucleosome ELISA
Human Bcl-2 protein and nucleosomes were quantified in HUVEC extracts by using the Bcl-2 and the nucleosome ELISA kits from Oncogene Research Products (Cambridge, Mass.) in accordance with the manufacturer's instructions. Readings of colored products were taken by using a spectrophotometer plate reader (Titertek Multiskan MCC) and compared with the standard curves. Values were expressed as units of Bcl-2 or nucleosomes/mg of protein.
Protein measurement
Protein concentration was determined in accordance with the method of Lowry et al. (23) .
CSA application
CSA was obtained either as a powder from Alexis Corporation (Läufelfingen, Switzerland) or as a solution in castor oil (Novartis, Pharma, Basel, Switzerland). CSA powder was dissolved in ethanol at 10 mM and brought to final concentrations in Medium 199. The CSA formulation in castor oil was dissolved in Medium 199. Similar effects were obtained with both formulations of CSA; control experiments with ethanol and castor oil ruled out a possible effect of the vehicle. As CSA binds to plasma proteins in vivo, the free CSA concentration ([CSA]) in serum-containing Medium 199 is expected to be lower than the analytical concentration (C tot ). 
Statistical analysis
Measurements are reported as mean Ϯ standard error of the mean (se). Analysis of HUVEC fluorescence shows the presence of cells with large differences in intensity, even in basal conditions. Accordingly, plots of average cellular fluorescence result in a bimodal distribution (data not shown), indicating that HUVECs may not be considered as a homogeneous population normally distributed. Consequently, the statistical significance of the differences in fluorescence observed before and after CSA application was assessed by either nonparametric tests (Mann-Whitney U test) or by 2-way analysis of variance (2-way ANOVA), using tabulated values of probabilities from the F distribution (24) .
RESULTS
Oxidative stress and apoptosis upon acute exposure to CSA
The relationship between oxidative stress and apoptosis in HUVECs during acute treatment with pharmacological concentrations of CSA was investigated by laser scanning confocal microscopy. Treatment of HUVECs with 200 M CSA causes an increase in the conversion of the oxidation-sensitive probe dihydro rhodamine 123 to its fluorescent analog rhodamine 123, which suggests an increased production of cellular oxidants in response to CSA. This fluorescence increase is illustrated in Fig. 1B 13 min after application of CSA, when a steady state has been reached, and may be compared to control conditions (Fig. 1A) .
2-way ANOVA for the effect of the duration of CSA application vs. control was carried out in 75 cells from three independent experiments and indicated that the increase in fluorescence induced by CSA was statistically significant after both 10 and 15 min of exposure to the drug (PϽ0.005 and PϽ0.001, respectively). Note that despite clear differences in fluorescence intensity between cells already present in control conditions, the average relative increase in fluorescence over basal values (see methods) induced by CSA was similar for all cells, averaging 105.4 Ϯ 11.9% (meanϮse) after 13 min of exposure to the drug. The increase in cellular oxidants monitored by the oxidation-sensitive probe is associated with an increased release of malonaldehyde and 4-hydroxyalkenals, by-products of lipid peroxidation (25) , in the culture medium from 9.6 Ϯ 0.7 pmol ml Ϫ1 in control conditions to 109.4 Ϯ 21.2 pmol ml the cytoplasmic indicator SNARF. As illustrated in Fig.  2 , when 200 M CSA treatment for 20 min had already caused an increase in rhodamine 123 fluorescence (green), there was the appearance of multiple cytoplasmic (white arrows) membrane blebs, an early sign of apoptosis ( Fig. 2A) .
Additional indications for the occurrence of apoptosis in response to 200 M CSA were assessed by staining the cells with acridine orange, a membrane-permeant and nucleic acid-intercalating probe. After 50 min from the application of 200 M CSA, clear changes in nuclear morphology, including chromatin condensation and lobule formation, were present (Fig. 2B) . Note that these early signs of apoptosis were not present simultaneously in every cell. CSA did not cause an acute release of lactic dehydrogenase, suggesting that pharmacological concentrations of CSA trigger an apoptotic rather than a necrotic process in HUVECs.
Molecular basis of CSA-induced damage
To assess the ability of HUVECs to complete the apoptotic process triggered by 200 M CSA, we performed DNA fragmentation analysis. As illustrated in To verify the role of oxidants in the proapoptotic effects of CSA, we performed quantitative estimates of DNA fragmentation by measuring the levels of nucleosomes with ELISA. Column bars of Fig. 3B indicate that in HUVECs acutely treated with CSA (200 M for 21 h), nucleosome levels increased from a control value of 0.6 Ϯ 0.1 U/mg protein to 29.3 Ϯ 2.3 U/mg protein. However, nucleosome levels in HUVECs treated simultaneously with 200 M CSA and either 300 M melatonin or 100 M Trolox (a water-soluble analog of vitamin E) were 27.8 Ϯ 1.0 or 27.3 Ϯ 2.0 U/mg protein, significantly higher than control levels (PϽ0.001 for both antioxidants) and not significantly different from CSA alone (1-way ANOVA). The increase in oligonucleosome formation was not significant 2 h after CSA application (data not shown), suggesting that an induction time is required for the activation of enzymes involved in DNA fragmentation.
To further characterize the molecular basis of the apoptotic process in consideration of the importance of antiapoptotic proteins, like Bcl-2, we measured the effects of acute CSA treatment on expression of the antiapoptotic protein Bcl-2 in HUVECs. Figure 3C shows that treatment with 200 m CSA for 21 h, which induces ladder-like DNA fragmentation, also induces a decrease in Bcl-2 protein expression from 4.6 Ϯ 0.1 U/mg protein (control) to 1.4 Ϯ 0.1 U/mg protein (treated cells); melatonin did not prevent Bcl-2 from falling to 1.8 Ϯ 0.3 U/mg of protein.
These results suggest that pharmacological levels of CSA affect HUVEC survival by altering the balance between pro-and antiapoptotic factors although by 
Effects of acute CSA treatment on endothelial cell density and morphology
This idea was further tested by observing the effects of CSA on HUVEC vitality. Treatment of HUVECs with 200 M CSA for 21 h causes a decrease in cell density (Fig. 4B) compared with control cultures (Fig. 4A) .
Moreover, the acute treatment also affects cellular morphology, with the appearance of round cells (arrows in Fig. 4B ) quite different from the typical polygonal shape of HUVECs (Fig. 4A) . Simultaneous treatment of cells with CSA and antioxidants such as Trolox (Fig. 4C) or melatonin (Fig. 4D) failed to prevent the effect of acute CSA treatment on HUVEC density. A similar lack of protection has also been noted with other antioxidants, such as ascorbic acid or N-acetylserotonin (data not shown). The failure of antioxidants to afford protection against the effects of acute treatment indicates that CSA triggers apoptotic cell death of HUVECs via an oxidative stress-independent mechanism.
Effects of chronic CSA treatment on endothelial cell density and morphology
As illustrated in Fig. 5 , chronic treatment of HUVECs with CSA (2 M for 8 days) did not appreciably affect cell density (Fig. 5B ) compared with control cultures (Fig. 5A) .
However, HUVECs treated with CSA have an altered morphology (Fig. 5B) , with a transition to an elongated shape, when compared with controls (Fig. 5A) . These morphological changes induced by chronic treatment with low CSA concentrations were suppressed by simultaneous treatment with Trolox (Fig. 5C ) or vitamin C (Fig. 5D) . A cobblestone morphology was also preserved with melatonin (data not shown). This indicates that chronic treatment with CSA may cause oxidative stress, which in turn affects the expression of specific proteins involved in maintaining the endothelial phenotype.
Oxidative stress on exposure to therapeutic levels of CSA
In agreement with this notion, confocal microscopy of EC exposed to CSA concentrations of clinical importance revealed an increased production of oxidants, albeit to a lower extent than in response to acute treatment. Figure 6 shows the increase in RHD 123 fluorescence in cells treated with 2.5 M CSA for 15 min (Fig. 6B ) compared with control conditions (Fig.  6A ) before CSA; 2-way ANOVA indicates that the increase in fluorescence is statistically different from controls 10 and 15 min after CSA application.
The average relative increase was 37.0 Ϯ 4.1%, calculated over 11 cells. Similar relative increase were measured in 70 cells from three independent experiments. In addition to the increased generation of oxidants monitored by DHR 123, chronic treatment of cells with 2.5 M CSA significantly increased the release of malonaldehyde and 4-hydroxyalkenals, as shown in Table 1 . Despite the generation of oxidants in response to therapeutic levels of CSA (2.5 M), no morphological signs of apoptosis were apparent (data not shown). Moreover, EC chronically treated (8 days) with 0.5-2.5 M CSA did not undergo nucleosomal-size DNA fragmentation, as shown in Fig. 7A . On the other hand, HUVECs surviving the chronic challenge with clinical levels of CSA show an increased expression of the antiapoptotic protein Bcl-2. Figure 7B shows that Bcl-2 protein expression significantly increased in cells exposed to chronic CSA treatment (0.5-2.5 M for 8 days).
Simultaneous treatment of EC with the antioxidant melatonin (300 M), which was ineffective in preventing the DNA degradation induced by 200 M CSA (see Fig. 4 ), suppresses the increase of Bcl-2 protein expression in response to 0.5-2.5 M CSA, suggesting that low levels of oxidants may act as signaling molecules that trigger the adaptation process (Fig. 7B) .
Chronic exposure to clinical concentrations of CSA induces adaptation and protects HUVECs against acute challenge with pharmacological CSA concentrations
To verify that clinical concentrations of CSA trigger an adaptation process, HUVECs were challenged with 200 M CSA after 6 day exposure to 2.5 M CSA. Data in Fig. 8 show that HUVEC cultures acutely challenged for 21 h with 200 M CSA have a significantly higher survival rate when chronically treated for 6 days with 2.5 M CSA (Fig. 8C ) than cultures not adapted to CSA prior to the acute challenge with the drug (Fig. 8B) .
Note that the cell density in Fig. 8C was significantly lower than in cultures treated for 6 days with control medium (Fig. 8A) 
DISCUSSION
The most significant novel finding of this paper is that CSA acts on HUVECs through two independent mechanisms, which operate at different concentrations and durations of exposure to the drug. The first mechanism operates for long exposures to clinical concentrations through an increase in cellular oxidants, which in turn causes a change in cell morphology and an up-regula- Note the lack of nucleosome increase in response to therapeutic concentrations of CSA. Results are the mean Ϯ se of three different experiments performed in duplicate. B) Column bars plot Bcl-2 protein levels in HUVECs cultured for 8 days in control medium or in the presence of CSA 0.5 or 2.5 M, either alone or in the presence of 300 M melatonin. CSA 0.5-2.5 M induced an increase in Bcl-2 levels. Bcl-2 levels were similar to control values when HUVECs were simultaneously treated with CSA and melatonin (MLT) 300 M. Treatment with MLT alone did not change control levels of Bcl-2 protein (data not shown). ***P Ͻ 0.001 tion of the antiapoptotic factor Bcl-2, suggesting the adaptation of HUVECs to oxidants. In sharp contrast, the second mechanism operates for short exposures to pharmacological concentrations and causes Bcl-2 down-regulation and apoptotic cell death by mechanisms independent of the concomitant CSA-induced oxidative stress.
We will next discuss the role that the properties of either CSA or HUVECs may play in eliciting the spectrum of responses to the drug. We will also discuss the possible clinical significance of adaptation to clinical concentrations of CSA through Bcl-2 up-regulation.
Pharmacological doses of CSA triggers oxidative stress-independent apoptosis in HUVECs
Pharmacological concentrations of CSA have been observed to cause oxidative stress in renal (31) and hepatic (5) tissues and in glioma cells (19) .
As oxidative stress is a well-known cause of apoptosis (17, 18), we investigated the ability of pharmacological doses of CSA to induce apoptosis in HUVECs. As shown in Figs. 2 and 3 , acute exposure to nonclinical levels of CSA concentrations induces both the morphological and biochemical hallmarks of apoptosis. Thus, CSAinduced apoptosis probably plays a role in the decrease in HUVEC density documented in Fig. 4B . However, the observation that simultaneous treatment with antioxidants does not suppress the biochemical markers of apoptosis (Fig. 3A) or the loss of HUVECs (Fig. 4C, D) , while blocking CSA-induced lipid peroxidation (16) , suggests that pharmacological concentrations of CSA induce apoptosis by mechanisms that operate independently of the simultaneously occurring oxidative stress.
Both CSA and its complexes with cyclophylins (32, 33) are known to exert several biological effects in target cells (for a review, see ref 34) , such as modulation of the protein phosphatase calcineurin (35) or of the permeability transition pore at the mitochondrial level (36) . Considering that CSA has previously been reported to protect cells from apoptosis because of its ability to block the mitochondrial permeability transition pore (37) , it seems unlikely that this mitochondrial action is responsible for CSA-induced apoptosis in HUVECs. Rather, the observation that apoptosis is independent of oxidative stress, despite the occurrence of lipid peroxidation in response to acute treatment with pharmacological concentrations of CSA (16), suggests that perhaps CSA protects HUVECs from oxidative stress-induced apoptosis.
On the other hand, inhibition of calcineurin (38) , a calcium-activated protein phosphatase that plays a key role in the immunosuppressive action of CSA, may have a causal role in CSA-induced apoptosis in HUVECs. Despite the lack of any direct evidence for a specific role of calcineurin in inducing oxidative stress in HUVECs, it seems reasonable to postulate that, in general, the interaction of the CSA/cyclophilins complexes with specific proteins may trigger an apoptotic program independently of oxidative stress. Further studies are required to define the molecular basis underlying the ability of CSA to induce both the increase in cellular oxidants and apoptosis and to elucidate the possible relationships between these two pathways of CSA action in HUVECs.
Clinical concentrations of CSA trigger oxidative stress-dependent adaptation in HUVECs
The observation that CSA-induced oxidants do not play a role in triggering apoptosis does not mean they are devoid of any effects in HUVECs. Indeed, antioxidants suppress the effects of clinical concentrations of CSA, including the up-regulation of Bcl-2 ( Fig. 7B) and the modification of cell morphology from a cobblestone to an elongated shape (Fig. 5B) . This suggests that clinical levels of CSA affect HUVECs through mechanisms regulated by oxidants and may also indicate that cellular oxidants are the second messengers mediating the effects of clinical levels of CSA in HUVECs.
It is important to note that the increase in oxidants takes place on a time scale of minutes, attaining a steady level as long as CSA is present in the medium, whereas the increase in Bcl-2 levels and the changes in cell morphology occur on a slow time scale, because they are present after 4 days but not after 24 h. This suggests that changes in Bcl-2 levels and cell shape represent a true adaptive response to a chronic increase in oxidants rather than a short-term response to a low level of oxidants.
The notion of an adaptive response to oxidants via an increase in Bcl-2 is further supported by the data in Fig.  8 , which show an improved cell survival to acute challenge with 200 M CSA after 6 days pretreatment with 2.5 M CSA that increases Bcl-2 levels.
Relationship between the level of CSA-induced oxidants, apoptosis and adaptation
Previous work with mammalian fibroblasts (see ref 39 for a recent review) indicates that the switch-over between adaptation and apoptosis may occur for increase of external H 2 O 2 between three-and sixfold. Moreover, recent data obtained in bovine EC exposed to carbon monoxide (CO) indicate that either adaptation or apoptosis develops within a less than 10-fold increase in environmental CO levels (40) . These data suggest that EC share with other mammalian cells the ability to trigger either an apoptotic or an adaptive response, the switch operating over a narrow range of concentrations of either oxidants or oxidant generators.
According to measurements based on laser scanning confocal microscopy, CSA induces an increase in the fluorescent signal of 30% and 100% over basal values in HUVECs exposed to CSA concentrations of 2.5 and 200 M, respectively. Assuming a linear relationship between oxidant levels and cellular fluorescence, a twofold increase in cellular oxidants may be lower than the threshold for triggering an apoptotic response. On the other hand, this increase is enough to cause lipid peroxidation (16) , which paves the way to apoptosis, but CSA-induced inhibition of the mitochondrial permeability transition pore may block the apoptotic response to CSA-induced oxidative stress. Furthermore, the possibility that the failure of oxidative stress to trigger apoptosis in HUVECs is related to differences between the factors regulated in CO-treated EC (i.e., superoxide dismutase and caspase-1) and in CSAtreated EC (Bcl-2) or to interspecies differences (human vs. bovine) may not be ruled out at this time. It must also be considered that CSA probably modulates the level of several pro-and antiapoptotic factors in EC, perhaps including caspases in addition to Bcl-2, and further studies will be required to address this issue. At clinical concentrations of CSA, a 30% increase over basal values of cellular oxidants may be enough to modulate Bcl-2 levels in a way similar to that reported for other mammalian fibroblasts and endothelial cells.
In conclusion, whereas the responses of HUVECs to acute treatment with pharmacological concentrations might mirror the presence of different branches in the CSA mechanisms of action, the ability to switch between adaptation and apoptosis for different levels of CSA may rely as much on the different effects of CSA on its target proteins as on the general properties of the response of HUVECs to cellular oxidants, which may operate independently to produce the full spectrum of drug effects in HUVECs.
Adaptation to oxidants generated in EC by clinical doses of CSA: friend or foe?
The observation that clinical doses of CSA may affect HUVECs through the generation of oxidants without causing apoptosis does not support a role for CSAtriggered apoptosis in the pathogenesis of vascular problems of transplanted patients. On the other hand, the up-regulation of Bcl-2, which occurs at clinical concentrations and indicates an adaptation to oxidants, may play a key pathogenetic role in these patients. The morphological changes observed in response to clinical levels of CSA with the loss of the cobblestone morphology typical of endothelial cells and the development of an elongated 'fibroblast-like' phenotype may indicate a loss of specialization that occurs in parallel to adaptation of HUVECs to CSA-induced oxidants.
By analogy with the increased resistance of cancer cells to antineoplastic drugs because of their increased content of Bcl-2 (41), the up-regulation by CSA-induced oxidants of Bcl-2 may increase the survival of functionally impaired HUVECs, as suggested by their altered morphology. Future studies are required to define the functional properties of HUVECs chronically exposed to clinical levels of CSA, with special reference to the regulation of ⅐ NO production, which may eventually affect the function of the vasculature.
Considering that endothelial cell lysis is an important step in the cascade of events responsible for hyperacute rejection of xenotransplanted organs (42) , the adaptive properties of endothelial cells may be useful to maintain the integrity of their membrane and its function as a selective barrier during hyperacute rejection. Recent results indicate that Bcl-2 transfection increases the ability of HUVECs to colonize and form new microvessels when xenotransplanted in immunodeficient mice (43) . A potential hazard of including HUVECs transfected by retroviral transduction into synthetic tissues intended for human use is the malignant potential of Bcl-2 overexpressing cells. However, we found no evidence for increased cell proliferation in HUVECs with up-regulated Bcl-2 levels. Furthermore, life-long treatment with CSA does not induce endothelial cell proliferation in transplanted patients, suggesting that Bcl-2
